# A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

> **NCT06388187** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 300 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06388187
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2026-04-22
- **Final completion:** 2026-04-22
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388187, "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06388187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*